BFS
APGE

Bare Financial Services’s Apogee Therapeutics APGE Stock Holding History

Bare Financial Services’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.37K Buy
48
+33
+220% +$2.97K ﹤0.01% 762
2026
Q1 		$1.26K Hold
15
– – ﹤0.01% 1153
2025
Q4 		$1.13K Buy
+15
New +$945 ﹤0.01% 1075

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Bare Financial Services's APGE Position: Q2 2026 in Review

Bare Financial Services increased its Apogee Therapeutics (APGE) stake by 220% in Q2 2026, buying an estimated $2.97K and bringing the position to 48 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #762.

Bare Financial Services first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Bare Financial Services held 48 shares of Apogee Therapeutics worth $6.37K as of Q2 2026.
  • Bare Financial Services bought 33 Apogee Therapeutics shares in Q2 2026, an estimated $2.97K.
  • Apogee Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #762 holding.
  • Bare Financial Services first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.